Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
about
Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a reviewBridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersOrganization of GABAergic synaptic circuits in the rat ventral tegmental areaEffects of etizolam and ethyl loflazepate on the P300 event-related potential in healthy subjects.Parasomnias: an updated review.Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressantsInteractions between disordered sleep, post-traumatic stress disorder, and substance use disordersThe Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder.Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant usersBenzodiazepine use and misuse among patients in a methadone programEffect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.Immunogold electron microscopic evidence of differential regulation of GluN1, GluN2A, and GluN2B, NMDA-type glutamate receptor subunits in rat hippocampal CA1 synapses during benzodiazepine withdrawal.Lormetazepam addiction: data analysis from an Italian medical unit for addiction.The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal NeurogenesisA novel therapy for REM sleep behavior disorder (RBD).High-dose benzodiazepine dependence: a qualitative study of patients' perception on cessation and withdrawal.First benzodiazepine prescriptions: qualitative study of patients' perspectives.Ethosuximide Reduces Mortality and Seizure Severity in Response to Pentylenetetrazole Treatment During Ethanol Withdrawal.Association Between Benzodiazepine Use and Epilepsy Occurrence: A Nationwide Population-Based Case-Control StudyEffects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats.The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic StudyPharmacotherapy of panic disorder.Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats.Increased AMPA receptor GluR1 subunit incorporation in rat hippocampal CA1 synapses during benzodiazepine withdrawalWeight and content uniformity of lorazepam half-tablets: A study of correlation of a low drug content product.Ten ways to improve the treatment of depression and anxiety in adults.Effects of CB1 and CRF1 receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: lack of withdrawal-like responses.Sustained benzodiazepine use in a community sample of older adults.Differential effects of lorazepam on sleep and activity in C57BL/6J and BALB/cJ strain miceRelative potency and effectiveness of flunitrazepam, ethanol, and beta-CCE for disrupting the acquisition and retention of response sequences in ratsBenzodiazepine prescription and length of hospital stay at a Japanese university hospital.Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.Benzodiazepine use in patients with chronic pain in an interdisciplinary pain rehabilitation program.Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient.Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention.Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report.Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.
P2860
Q24647208-7CD90C6F-3DD5-49F2-BB3F-E6CD417EB127Q26800235-9F4D1937-2D24-43EC-8EB8-B01A7CC4703CQ27009995-AED72CC9-DB78-4AA7-8029-8DFDBEDC9C30Q28484279-93EE4B25-4DB8-4E7A-90F1-251721DF5876Q30478571-E4B8E443-3C24-4CCE-98F2-0069FAE4791BQ30526455-F1FE4013-8118-4CA2-B77D-9BE5C8601024Q30887852-18F632D6-5F28-4D09-9C5E-5623D5B378E4Q33736941-91F311D9-EA09-4BB8-94FB-DB756D765F68Q33740428-D8D28E17-1D18-4EC1-8D8E-145A7BBB026BQ33817870-6609BF4A-B084-4B25-A90F-7425612ACA05Q33906067-5E46C9FB-90FC-4FB7-873D-7D6B38B8E35CQ33961092-701B9ED3-170E-494E-8A7F-4D69666767C0Q34147347-C966EF5D-8162-416C-BF94-ED94377F212BQ34335439-B83425BF-7EDC-4D5C-A101-29676BDD153DQ34525841-58FE99F5-C2B4-4B9A-AAEC-D85CD73A1A49Q35098031-ED662AE3-AF9C-46C8-97AE-12EAA6A517FAQ35240385-149A5891-61C6-4E9F-A4F0-A04AD1C32BCAQ35583079-0C0DA7D0-6A80-4570-8E3B-68D85212CDA3Q35629095-F50A7DC8-E3B1-4AE9-96B7-A44D57D78D44Q35942199-659CC404-4B1A-4B2D-9EC0-AA7E400322C9Q35956950-2EFB2857-A21D-4172-B2C8-CF948DC11EC4Q36256161-7C1EA206-52B5-4E52-B33C-D591C6070F12Q36298192-15E7F542-B51F-4C48-8538-2218B7A22F0FQ36873006-328282D4-BD30-4243-A4C5-0F7380989423Q36876452-A35AB2CC-5B00-40DD-9B20-BD2339A4006EQ36930875-DF80BA39-C3FF-4FB0-8AFB-17363B631AE6Q36993994-DBEB5ECA-AFE9-4A0C-8172-ECB82920FB9EQ37098990-75E0FC43-9DB8-48F5-872A-523067AE6C06Q37294169-395ACB42-B985-47B4-9416-30CCC80F2621Q37302152-5706CD3B-6507-4B37-ADF8-B7400EC7A94CQ37337025-E44933E9-D746-4DFE-986F-009036608564Q37347970-4D6EE411-6BFD-4FCE-A543-7352C797F7B7Q37363653-995D7B1F-F8FE-4528-ACF6-5596B2E75647Q37396729-E3633EBB-1048-4EC2-9B19-4EDDD2AB489BQ37547290-3778DDA2-C2EC-4C83-AA8F-800F35658163Q37643464-C0B445DC-0D8B-4D6E-96FF-8BE31BD26C16Q39617566-88236714-304F-4D5B-9D43-076818A1A7E3Q42102802-487B9EF7-54FC-44A8-94D5-BABA7FB8BB4CQ43248865-04EB0B64-22CE-4550-90F3-FD745D9BFA83Q45056140-CBC952F7-A427-4DDC-B57B-5B036628166A
P2860
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@ast
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@en
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@nl
type
label
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@ast
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@en
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@nl
prefLabel
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@ast
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@en
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
@nl
P1476
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound
@en
P2093
Guy Chouinard
P478
65 Suppl 5
P577
2004-01-01T00:00:00Z